Vertex Pharmaceuticals · 2 days ago
Vertex Fellow San Diego
Vertex Pharmaceuticals is a global biotechnology company committed to advancing transformative science. The Vertex Fellowship is a unique, one-year training program for outstanding scientists and physicians, providing hands-on experience with real-world R&D challenges and mentorship from Vertex leaders.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Embed for one year within a Vertex project team
Work on a project of relevance, based on your skills and our pipeline needs
Receive guidance from scientific, medical, and business leaders at Vertex
Develop connections internally and externally
Qualification
Required
PhD, MD, or joint degree attained within 0-5 years
Demonstrated scientific impact (e.g., peer-reviewed publications, presentations, awards)
Evidence of creative thinking, scientific problem solving, and innovation
Interest in learning how scientific research leads to the development of therapies
Benefits
Medical, dental and vision benefits
Generous paid time off (including a week-long company shutdown in the Summer and the Winter)
Educational assistance programs including student loan repayment
A generous commuting subsidy
Matching charitable donations
401(k)
Company
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
H1B Sponsorship
Vertex Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (188)
2024 (150)
2023 (111)
2022 (164)
2021 (112)
2020 (80)
Funding
Current Stage
Public CompanyTotal Funding
$657.31MKey Investors
Janssen Belgium
2024-07-10Post Ipo Secondary· $1.11M
2022-05-17Post Ipo Equity· $50M
2009-12-03Post Ipo Equity· $443M
Leadership Team
Recent News
2026-01-05
2026-01-05
Company data provided by crunchbase